Application of multiplexed ion mobility spectrometry towards the identification of host protein signatures of treatment effect in pulmonary tuberculosis.

ABSTRACT:

Rationale

The monitoring of TB treatments in clinical practice and clinical trials relies on traditional sputum-based culture status indicators at specific time points. Accurate, predictive, blood-based protein markers would provide a simpler and more informative view of patient health and response to treatment.

Objective

We utilized sensitive, high throughput multiplexed ion mobility-mass spectrometry (IM-MS) to characterize the serum proteome of TB patients at the start of and at 8 weeks of rifamycin-based treatment. We sought to identify treatment specific signatures within patients as well as correlate the proteome signatures to various clinical markers of treatment efficacy.

Methods

Serum samples were collected from 289 subjects enrolled in CDC TB Trials Consorti

SUBMITTER: Kedia K 

PROVIDER: S-EPMC6181582 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature